Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7087 USD | +2.12% | +0.52% | -25.20% |
Financials (USD)
Sales 2024 * | 2M | Sales 2025 * | 3.33M | Capitalization | 51.59M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -106M | EV / Sales 2024 * | 25.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 15.5 x |
P/E ratio 2024 * |
-0.57
x | P/E ratio 2025 * |
-0.58
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.16% |
Latest transcript on Kezar Life Sciences, Inc.
1 day | +2.12% | ||
1 week | +0.52% | ||
Current month | +2.12% | ||
1 month | -17.08% | ||
3 months | -31.19% | ||
6 months | -15.44% | ||
Current year | -25.20% |
Managers | Title | Age | Since |
---|---|---|---|
Christopher Kirk
FOU | Founder | 52 | 15-02-18 |
John Fowler
FOU | Founder | 52 | 15-02-18 |
Marc Belsky
DFI | Director of Finance/CFO | 68 | 18-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 15-12-31 |
Graham Cooper
CHM | Chairman | 54 | 17-09-30 |
Michael Kauffman
BRD | Director/Board Member | 60 | 16-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.02% | 1,487 M€ | +7.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 0.7087 | +2.12% | 337,311 |
24-05-31 | 0.694 | +1.40% | 475,630 |
24-05-30 | 0.6844 | -0.62% | 845,539 |
24-05-29 | 0.6887 | -3.27% | 679,903 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.20% | 50.52M | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- KZR Stock